Slide 1: Full Year and Fourth Quarter 2017
Full Year and Fourth Quarter 2017 Trusted by the Life Sciences Industry NASDAQ: CYRX
Slide 2: Safe Harbor – Forward Looking Statements
Safe Harbor – Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans
Slide 3: Overview
Overview Leading temperature-controlled logistics solutions provider for the life sciences industry with a focus on Business description the regenerative medicine market (CAR-T) Clients Pharmaceutical and biotechnology companies (Novartis, Gilead/Kite(a), TiGenix, etc.) Business Segments Biopharma,
Slide 4: Cryoport Underwent Several, Material, Positive Changes in 17
Cryoport Underwent Several, Material, Positive Changes in 2017 March 2017 Current (March 2018) 0 approved CAR-T therapies 2 approved CAR-T therapies 0 commercial CAR-T agreements 2 commercial CAR-T agreements with the leading CAR-T biopharma companies (Novartis and Kite) 129 Clinical trials supporte
Slide 5: New Cryoport Shipping Products
New Cryoport Shipping Products • SafePak & SafePak XL Used in Cryoport dry shippers Tyvek provides a leak-proof microbial barrier Canes, small vial boxes, plastic goblets Cryovial boxes, blood cassettes, odd-shaped payloads Safepak systems reduce risk of cross contamination and decon proce
Slide 6: Case Study—Autologous CAR-T
Case Study—Autologous CAR-T Clinical trial (PH I/II) Patients: 20 (UK only) Logistics: Donation and therapy Supply Chain: Vector (1 per trial) Shipments: 41
Slide 7: Case Study—Autologous CAR-T
Case Study—Autologous CAR-T Early market supply Clinical trial (PH I/II) Patients: 2,000 (Europe) Logistics: Donation and therapy Patients: 20 (UK only) Vector (5/yr) Infusion kits (1/patient) Logistics: Donation and therapy Supply Chain: Labels (1/patient) Supply Chain: Vector (1 per trial) Storage
Slide 8: Case Study—Autologous CAR-T
Case Study—Autologous CAR-T Early market supply Early market supply Clinical trial (PH I/II) 2,000 (Europe) Patients: 2,000 (US) 2,000 (Asia) Patients: 2,000 (Europe) Logistics: Donation and therapy Logistics: Donation and therapy 3x Manu Sites Patients: 20 (UK only) Vector (5/yr) Vector ( 15/yr) In
Slide 9: Clinical Trials Drive Revenue Growth
Clinical Trials Drive Revenue Growth FDA Approvals: - Novartis (KymriahTM) - Kite Pharma (YescartaTM) 214 172 26 17 82 95 93 73 Potential Annual Revenue per Trial ($15-75K) ($75-150K) ($200K-1M) ($ ($2M-20M) NASDAQ: CYRX
Slide 10: Example Auto EU Supply Chain
Example Auto EU Supply Chain Media, beads, consumables Apheresis Kit Viral Vector Proleukin/IL-2, WFI Patient Cells PBMCs EU CMO Modified Cells in QP Release Modified Cells i Manufacture EU PATIENT Follow up samples USA Uncontrolled 2-8°C Cryogenic -80°C
Slide 11: No Other Player – with Comprehensive Logistics Solutions for the Regenerative Therapy Market
No Other Player – with Comprehensive Logistics Solutions for the Regenerative Therapy Market Primary focus is on the large and rapidly growing Offers a comprehensive suite of solutions not Regenerative Therapy market available from any competitor Global regenerative therapy market expected to grow t
Slide 12: Cryoport is Supporting the Commercialization of Kymriah
Cryoport is Supporting the Commercialization of Kymriah, Novartis’ First-to-Market CAR-T Cell Therapy Cryoport is the exclusive cryogenic logistics provider for Kymriah – 3 year agreement with renewal rights Novartis received first ever FDA approval for a CAR-T cell therapy, Kymriah™ (CTL019), for c
Slide 13: Cryoport Chosen to Support the Launch of Kite/Gilead's Yescarta
Cryoport has been Chosen to Support the Launch of Kite/Gilead’s CAR-T, Yescarta, which was Approved in October 2017 Cryoport is the exclusive cryogenic logistics provider for Yescarta – 3 year agreement with renewal rights For the past three decades, Kite has been at the forefront of cancer immunoth
Slide 14: Commercial Success Relies on Strong Partnerships
Commercial Success Relies on Strong Partnerships High-touch services that enhance patient outcomes, mitigates financial burden and generates data to align with value-based outcomes is imperative Patient Patient Ordering/ Patient Access Treatment Transport Cell and Gene Ultra-frozen Treatment Patient
Slide 15: Client Base of Leading Companies
Client Base of Leading Companies Biopharma Reproductive Medicine Animal Health NASDAQ: CYRX
Slide 16: Primary Target Market: Regenerative Therapy
Primary Target Market: Regenerative Therapy Inflection point: Commercialization Ph. I: 314 has begun Novartis’ CAR-T drug, Kymriah, 946 (a) (192 in 2015) Ph. II: 550 approved in August 2017 and Gilead/Kite therapy, Yescarta, approved in October 2017 At least 5-7 additional BLA/EMAs Clinical trials u
Slide 17: CryoStork for Reproductive Medicine
CryoStork℠ for Reproductive Medicine
Slide 18: Cryoport is at an Important Inflection Point
Cryoport is at an Important Inflection Point Cryoport holds commercial support agreements with the two currently most important players (Novartis and Gilead/Kite Pharma) in the expanding CAR-T space Commercial agreements represent large sources of future revenue - considerably beyond what is achieve
Slide 19: C3 Shipper for Clients Requiring Reliable 2-8°C Logistics Solutions
C3TM Shipper for Clients Requiring Reliable 2-8°C Logistics Solutions The introduction of C3TM means that Cryoport supports the entire logistics continuum for regenerative medicine clinical and commercial programs The C3TM Solution seamlessly integrates Cryoport’s expertise in packaging, informatics
Slide 20: Revenue Trends
Revenue Trends All biopharma growth to-date has been generated without commercial assets 2017 over 2016 growth: +71.9% +11.4% +34.3% NASDAQ: CYRX
Slide 21: Cryoport has a Scalable Business Model
Cryoport has a Scalable Business Model Continuing double-digit growth in all markets fueled by biopharma - increased 71.9% from 2016 to 2017 Net revenue for 2017 vs. prior years ($mm) Gross margin % for 2017 vs. prior years $12.0 $12.0 50.0% 49.9% $11.0 55.7% $10.0 40.4% 40.0% $9.0 $7.7 $8.0 39.0% 3
Slide 22: Clinical Trials Drive BioPharma Revenue Growth
Clinical Trials Drive BioPharma Revenue Growth Number of 250 10 $ Million clinical trials $9.1 m 9 200 26 8 7 150 6 $5.3 m Phase III 93 5 Phase II 18 Phase I 100 4 BioPharma Revenues $m $3.4 m 58 3 50 10 95 2 25 53 1 19 0 0 2015 2016 2017 As of December 31
Slide 23: Financial Summary
Financial Summary Statements of Operations Data: (in thousands) 2012 2013 2014 2015 2016 2017 YoY growth % Net Revenues $ 863 $ 2,194 $ 3,572 $ 5,525 $ 7,679 $ 11,954 55.7% Biopharma 704 1,105 1,736 3,364 5,302 9,113 71.9% Animal Health - 627 940 869 845 1,135 34.3% Reprodcutive Medicine 159 462 896
Slide 24: Key Highlights
Key Highlights Twelve month revenue growth of 56% year over year Impressive Three month revenue growth of 49% year over year revenue growth driven Supporting Novartis’ commercial launch of Kymriah by robust pipeline Supporting Kite’s commercial launch of Yescarta Biopharma revenue up 72% for twelve
Slide 25: Thank you!
Science. Logistics. Certainty. Thank you! NASDAQ: CYRX